This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly basis. It is based on Robbins’ regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Larry Robbins’ Glenview Capital Management Portfolio article for an idea on his investment philosophy and our previous update for the fund’s moves during Q4 2019.
This quarter, Robbins’ 13F portfolio value decreased ~68% from $11.42B to $3.68B. The number of holdings decreased from 50 to 44. The top five positions are Takeda Pharmaceutical, Tenet Healthcare,